Streptase Side Effects
Generic Name: streptokinase
Note: This page contains side effects data for the generic drug streptokinase. It is possible that some of the dosage forms included below may not apply to the brand name Streptase.
It is possible that some side effects of Streptase may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to streptokinase: powder for solution
As well as its needed effects, streptokinase (the active ingredient contained in Streptase) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking streptokinase, check with your doctor or nurse immediately:More common
- Blurred vision
- dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
- unusual tiredness or weakness
- Blood in stool
- blood in urine
- nose bleeds
- red or purple spots on skin
- unusual bruising
- vomiting blood
- Abdominal pain or swelling
- back pain or backaches
- black, tarry stools
- burning, itching, redness, or soreness of skin
- cloudy urine
- cold clammy skin
- coughing up blood
- difficulty with breathing
- difficulty with swallowing
- fast heartbeat
- fast, weak pulse
- feeling of warmth
- greatly decreased frequency of urination or amount of urine
- hives or welts
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- muscle or bone pain
- nausea and vomiting
- noisy breathing
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the face, neck, arms, and occasionally, upper chest
- shortness of breath
- skin rash
- tightness in chest
For Healthcare Professionals
Applies to streptokinase: injectable powder for injection
Predisposing risk factors for the development of intracranial hemorrhage during thrombolytic therapy for myocardial infarction have included body weight less than 70 kg, age greater than 65 years old, and preexisting anticoagulant therapy. The authors of GISSI concluded that the risk of hemorrhagic stroke is also directly related to Killip classification.
A meta-analysis of 30 studies dealing with proximal lower extremity deep vein thrombosis (DVT) has revealed the following relative risks for patients who received SK + heparin versus heparin alone: any major bleeding, 2.9; central nervous system (CNS) bleeding, 4.5; mortality from CNS bleeding, 4.0; pulmonary embolism (PE), 1.0; mortality from PE, 1.0; postphlebitic syndrome, 0.4.
The risk of hemorrhagic side effects from streptokinase (the active ingredient contained in Streptase) can be minimized with patient selection. Major risk factors for intracranial hemorrhage have included known intracranial tumor, prior neurosurgery, stroke within the past six months, head trauma within the past month. Other significant risk factors included severe, uncontrolled hypertension, a remote stroke known not to be hemorrhagic, recent transient ischemic attacks, advanced age, and female gender.
Hematologic side effects of streptokinase (SK) have included minor and major bleeding. The risk of bleeding appears to be significantly increased when plasma fibrinogen levels fall below 250 mg/dl. Minor bleeding has occurred in up to 67% of patients, presenting as venipuncture or arterial cutdown site oozing, microscopic hematuria, hemoptysis, or hematemesis. Local bleeding usually has been controlled by manual compression for 20 to 30 minutes. Serious or major bleeding, including gastrointestinal, genitourinary, joint, retroperitoneal or intracerebral hemorrhage, has occurred in 0.3% to 6.0% of patients. Adjuvant heparin, but not aspirin, therapy appears to increase the risk of bleeding.
Intracranial hemorrhage in 0.1% to 1.0% of patients and rare cases of intramyocardial hemorrhage have been reported. Several fatalities due to intracranial or retroperitoneal hemorrhage have occurred during thrombolytic therapy.
Rare cases of embolization and anti-SK-mediated platelet aggregation during or after SK therapy have been reported. There is speculation that fibrinolysis could increase pericatheter thrombosis, which can result in local or distal thromboembolism.
The overall incidence of hypersensitivity reactions to SK from the ISIS-2, GISSI-1 and GISSI-2 data ranged from 1.6% to 4.4%. Smaller studies have reported an incidence of 2% to 6%. Acute allergic reactions to SK ranged from minor dyspnea, urticaria, pruritus, flushing, nausea, headache, or musculoskeletal pain to severe anaphylaxis, bronchospasm, or periorbital or angioneurotic edema. SK-induced fever has been reported in 30% to 50% of patients. Severe acute hypersensitivity reactions have usually required discontinuation of therapy, antihistamines, and/or corticosteroids. In rare cases, adrenergic agents have been required to treat anaphylactic shock.
In the 8,592 patients in the ISIS-2 trial who received SK there were no confirmed incidences of anaphylactic shock. The GISSI study 7 incidents of nonfatal anaphylactic reactions among 5,860 patients who had received SK (0.1%), though 99 patients (1.7%) had allergic reactions severe enough to discontinue therapy and another 42 (0.7%) were identified retrospectively. Skin testing immediately before SK therapy appears to be a practical, sensitive, and specific tool to help identify patients at risk for anaphylaxis.
Since cardiovascular side effects may be more likely among the population of patients in whom SK in indicated, a cause-and-effect relationship to the drug is not always clear. Transient hypotension has been reported during SK therapy in approximately 40% of patients (anterior or inferior wall MI). Hypotension has been associated with reperfusion, which has been associated with decreased in-hospital mortality. Reperfusion of the myocardium has resulted in arrhythmias in 80% of patients who experience reperfusion. The most common reperfusion arrhythmia is a transient accelerated idioventricular rhythm, which is typically clinically benign. Premature ventricular depolarizations during reperfusion do not necessarily predict severe ventricular arrhythmias.
Dyspnea, cyanosis, rare cases of hemorrhagic myocardial infarction, serious ventricular arrhythmias, hemopericardium, and death from cardiogenic shock have been associated with thrombolytic therapy, in general.
Rare cases of cholesterol embolization syndrome have been associated with SK and other thrombolytic agents.
Cholesterol embolization, a rare syndrome that typically presents with painful ischemia or necrosis of the digits, myalgias, skin changes of livedo reticularis and often progresses to renal failure and death, has occurred. Other findings have included cyanosis, ulcers, gangrene of the hands and feet, myalgias, intestinal infarction or eosinophilia. The exact mechanism is not known, but is believed to be due to physical disruption of atheromatous plaques by lysis of platelet-fibrin thrombi.
New or worsened renal impairment has been associated with SK-induced immune complex disease. Rare cases of mild and transient acute renal insufficiency with proteinuria without evidence of hypersensitivity have been described after SK therapy.
The differential diagnosis of acute renal failure following SK therapy includes ischemic injury, immunologic injury, and postrenal obstruction. Ischemia may be due to low cardiac output or hypotension secondary to acute myocardial infarction (if present), a direct effect of SK, reperfusion-induced hypotension, or hemorrhagic shock. These conditions may cause acute tubular necrosis. Ischemia may also be due to emboli from mural thrombi (if present), cholesterol emboli syndrome, or myoglobinuria.
Immunologic injury to the kidney may be related to SK-induced serum sickness, Schonlein-Henoch purpura, or immune complex nephritis.
Retroperitoneal hemorrhage or ureter thrombosis during or following SK therapy can cause postrenal obstruction.
In one case of Guillain-Barre syndrome (GBS) associated with SK oligoclonal IgG bands in the cerebrospinal fluid and serum were shown to be specific for streptokinase (the active ingredient contained in Streptase) Clinical symptoms of GBS were thought to result from SK-antibody complex-mediated damage to the local blood-nerve barrier.
Hemorrhagic stroke, a potentially serious nervous system side effect, has affected approximately 0.1% to 1.0% of patients. Extremely rare cases of Guillain-Barre syndrome have been associated with the use of SK.
Gastrointestinal side effects have been rare. Hemorrhagic gastritis has been associated with the thrombolytic state. Nausea or vomiting has been reported during thrombolytic therapy. Unusual cases of hemorrhagic splenic rupture and subcapsular hepatic hematoma have occurred.
Rare cases of SK-induced hepatic dysfunction have been reported . Some experts believe that mild, transient liver function test elevations indicative of cholestasis do not appear to be caused by toxic or allergic effects of SK itself, but by the high activities of the proteolytic enzymes, plasminogen activator and plasmin. Rare cases of jaundice have been reported.
In a prospective study of 24 nonselected patients with peripheral arterial occlusions undergoing SK therapy, 18 had significant liver enzyme elevations typical of cholestasis and impaired hepatocellular integrity and function, but none became jaundiced.
Rare cases of musculoskeletal back pain have been reported. In some cases bleeding into the iliopsoas muscles was discovered, but in most reported cases, there was no evidence of allergy, aortic dissection, worsened myocardial infarction or retroperitoneal hemorrhage.
A genitourinary concern for menstruating women who are considered for thrombolytic therapy has been whether SK can safely be used during menses. The drug has been used safely during menses, perhaps because hemostasis of the uterine endothelium after the first day of menses depends on arteriolar vasoconstriction more than the formation of fibrin.
Adult respiratory distress syndrome (ARDS) has been rarely associated with the use of SK. ARDS is a known complication of hypersensitivity to SK.
Dermatologic side effects have included rare cases of dermal microemboli. Some cases have progressed to dermal necrosis.
SK is antigenic and may induce the formation of antibodies. Delayed hypersensitivity reactions may result in the development of immune complex disease, presenting as fever, vasculitic or purpuric rashes, abnormal renal and liver function tests, arthralgias, serum sickness, and/or a syndrome resembling adult respiratory distress syndrome. A case of SK-induced direct antiglobulin test-positive hemolysis has been reported.
The production of the general body symptom, fever, has also been associated with urokinase, which is not antigenic. While the mechanism of fever is not known, this suggests that fever may be due to breakdown products of thrombi rather than to thrombolytic drugs.
More about Streptase (streptokinase)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.